Role of vitamin D supplementation in improving disease activity in rheumatoid arthritis: An exploratory study
International Journal of Rheumatic Diseases, Article first published online: 20 OCT 2015, DOI: 10.1111/1756-185X.12770
S. Chandrashekara* and Anand Patted
6 weeks of 60,000 IU/week, then 3 months of 60,000 IU/month
|Vitamin D||10 ng||57 ng|
See also VitaminDWiki
- Overview Rheumatoid Arthritis and vitamin D
- Active Rheumatologic disease was 5X more likely with low vitamin D – June 2013
- Big increase in vitamin D supplementation in just 2 years after Swiss rheumatology report – Dec 2013
- 100 percent of rheumatoid arthritis patients with very low vitamin D had very severe RA – Jan 2013
- 300,000 IU every 3 months helped raise vitamin D levels in half of RA patients – April 2012
- Overview Loading of vitamin D
Intervention AND Rheumatoid Arthritis
- Rheumatoid Arthritis pain reduced by monthly 100,000 IU of Vitamin D – Oct 2018
- Rheumatoid arthritis reduced by 440,000 IU of Vitamin D over 4 months – Oct 2015
- High dose vitamin reduced pain of fibromyalgia, osteoarthritis, and rheumatoid arthritis - July 2015
- Just 500 IU of vitamin D helped reduce rheumatoid arthritis pain - RCT Oct 2011
The aim of this exploratory study is to estimate the relationship between vitamin D (vit D) deficiency and active rheumatoid arthritis (RA), and the role of supplementation in improving disease activity.
A randomized recruitment, consent screening, open-label interventional study was conducted in patients who fulfilled American College of Rheumatology/European League Against Rheumatism 2010 criteria for diagnosing RA and on stable disease-modifying anti-rheumatic drugs (DMARDs) for 3 months. Serum vit D levels and Disease Activity Score of 28 joints/C-reactive protein (DAS28-CRP) disease activity status were estimated at the first visit. Subjects with low vit D levels and DAS28-CRP > 2.6 were supplemented with vit D for 12 weeks, and were assessed for improvement in disease activity and serum vit D levels.
One hundred and fifty RA patients of mean age 49 ± 12.1 years, mean duration of illness 78 ± 63 months, and on treatment with DMARDs for 44 ± 39 months were recruited for the study. Of these, 73 (49%) subjects were found to have DAS28-CRP > 2.6 and serum vit D below 20 ng/mL. The patients received vit D supplement of 60 000 IU/week for 6 weeks, followed by 60 000 IU/month for a total duration of 3 months. Disease activity and vit D status were assessed for 59 (80.8%) patients who reported at the end of 12 weeks of treatment. Mean DAS28-CRP of these patients showed a statistically significant improvement from 3.68 ± 0.93 at baseline to 3.08 ± 1.11 after supplementation (P = 0.002). Serum vit D levels improved from 10.05 ± 5.18 to 57.21 ± 24.77 ng/mL (P < 0.001) during the period.
Supplementation of vit D in RA patients with persisting disease activity and vit D deficiency contributed to significant improvement in disease activity within a short duration.